drugset / Trial / NCT02779699
A Study of AL2846 on Tolerance and Pharmacokinetics
NaSingle-groupOpen-labelTreatment
Summary
A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.
Timeline
- Start
- 2016-05
- Primary completion
- 2020-10
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AL2846 | Small molecule | — | Oral |
Indications
No indication recorded.